SEROPREVALENCE OF MEASLES IgG ANTIBODIES IN CHILDREN OF SCHOOL GOING AGE

Authors

  • Saiba Ferdoos Department of Biotechnology, University of Azad Jammu & Kashmir, Muzaffarabad
  • Shakir Khan Department of Biochemistry, Margalla Institute of Health Sciences, Rawalpindi
  • Zahid Azeem Department of Biochemistry, AJK Medical College, Muzaffarabad
  • Abdul Khaliq Naveed Department of Biochemistry, Islamic International Medical College, Rawalpindi
  • Ghazanfar Ali Department of Biotechnology, University of Azad Jammu & Kashmir, Muzaffarabad
  • Nazia Malik Department of Biotechnology, University of Azad Jammu & Kashmir, Muzaffarabad
  • Syed Sohail Zahoor Zaidi Department of Biotechnology, University of Azad Jammu & Kashmir, Muzaffarabad

DOI:

https://doi.org/10.69656/pjp.v14i1.140

Keywords:

Seroprevalence, Measles, IgG, Antibodies, School-going, Children

Abstract

Background: Measles is highly contagious infectious disease and considered to be leading cause of death among young children. Although vaccination process of measles is well ascertained but still its associated morbidity and mortality is high among children of developing countries. This study was designed to see the level of measles IgG in children in District Bagh of Azad Jammu & Kashmir. Methods: Measles IgG antibodies were screened in total of 250 school going children (4–8 years) in the District Bagh, Azad Jammu and Kashmir were enrolled. The subjects were grouped on age basis; Group A had children of 4–5 years, Group B comprised of children of 5–6 years, Group C contained children of 6–7 years and Group D had age 7–8 years. A The collected samples were transferred to the Molecular Virology Laboratories at National Institute of Health (NIH), Islamabad for detection of measles IgG antibodies. Measles antibodies were estimated by using kits for Enzyme Linked Immunosorbant Assay. Results: There were 10 (4%) children in Group A, 18 (7.2%) were in Group B, 42 (16.8%) were in Group C, and 180 (72%) children were in Group D. Out of 250 children 61 (24.4%) were detected as unprotected and 13 (5.2%) were at borderline and 176 (70.4%) had protective antibody level against the measles virus. Conclusion: Significant number of children is under potential risk to develop measles infection. No significant relation could be established between disease, age, and gender.

Pak J Physiol 2018;14(1):13–5

Downloads

Download data is not yet available.

Author Biography

Zahid Azeem, Department of Biochemistry, AJK Medical College, Muzaffarabad

HoD Biochemistry, AJK Medical College, Muzaffarabad

References

1. Gaafar T, Moshni E, Lievano F. The challenge of achieving measles elimination in the Eastern Mediterranean Region by 2010. J Infect Dis 2003;187:S164–S171.
2. Ovsyannikova IG, Jacobson RM, Vierkant RA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004;22:1914–20.
3. Cutts FT, Henao-Restrepo A, Olive JM. Measles elimination: progress and challenges. Vaccine 1999;17(3):47–52.
4. Gdalevich M, Robin G, Mimouni D, Grotto I, Shpilberg O, Ashkenazi I. Measles antibody prevalence rates among young adults in Israel. Am J Infect Control 2002;30(3):165–9.
5. Bilkis MD, Barrero PR, Mistchenko AS. Measles resurgence in Argentina: 1997–1998 outbreak. Epidemiol Infect 2000;124:289–93.
6. Whittle H, Aaby P, Samb B, Cisse B, Kanteh F, Soumare M Simondon F. Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines. Pediatr Infect Dis J 1999;18(1):53–7.
7. Ali G, Zaidi SSZ, Zaman N. Seroprevalence of measles antibodies in children at school going age in Islamabad, Pakistan. Pak J Med Res 2009;48:31–5.
8. Tricou V, Pagonendji M, Manengu C, Mutombo J, Mabo RO, Gouandjika I. Measles outbreak in Northern Central African Republic 3 years after the last national immunization campaign. BMC Infect Dis 2013;13(1):103.
9. Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: A 12-year follow-up in two cohorts. Vaccine 1998;16:2052–7.
10. Gozalan A, Korukluoglu G, Kurtoglu D. Measles seroepidemiology in 3 cities in Turkey. Saudi Med J 2005;26:1971–7.
11. Kamat M, Pyati S, Pildes RS. Measles antibody titers in early infancy. Arch Pediatr Adolesc Med 1994;148:694–8.
12. Shann F, Steinhoff M. Vaccines for children in rich and poor countries. The Lancet 1999;354:7–11.
13. Isik N, Uzel N, Gokcay G. Seroconversion after measles vaccination at nine and fifteen months of age. Pediatr Infect Dis 2003;22:691–5.
14. Pannuti CS, Morello RJ, Moraes JC. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diagn Lab Immunol 2004;11:119–22.
15. Cox MJ, Azevedo RS, Massad E. Measles antibody levels in a vaccinated population in Brazil. Trans R Soc Trop Med Hyg 1998;92:227–30.
16. Tayil SE, Shazly MK, Amrawy SM, Ghouneim FM, Abou Khatwa SA, Masoud GM. Sero-epidemiological study of measles after 15 years of compulsory vaccination in Alexandria, Egypt. East Mediter Health J 1998;4(3):437–47.
17. Mossong J, O’Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000;19(4):523–9.
18. Sadaruddin A, Ghafoor F, Alam S, Sumera N, Khan I, Mohyuddin G, et al. Seroprevalence of Measles Antibodies in School going Children in Pakistan. Pak J Med Res 2012;51:38–41.
Pak J Physiol 2018;14(1)

Downloads

Published

31-03-2018

How to Cite

1.
Ferdoos S, Khan S, Azeem Z, Naveed AK, Ali G, Malik N, et al. SEROPREVALENCE OF MEASLES IgG ANTIBODIES IN CHILDREN OF SCHOOL GOING AGE. Pak J Phsyiol [Internet]. 2018 Mar. 31 [cited 2024 Dec. 21];14(1):13-5. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/140

Issue

Vol. 14 No. 1 (2018): Pakistan Journal of Physiology

Section

Original Article

License

Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.